Lantern Pharma Inc logo

Lantern Pharma Inc

NAS:LTRN (USA)   Ordinary Shares
$ 5.85 +0.0399 (+0.69%) 11:20 AM EST
At Loss
P/B:
1.76
Market Cap:
$ 62.94M
Enterprise V:
$ 24.34M
Volume:
29.67K
Avg Vol (2M):
134.62K
Volume:
29.67K
At Loss
Avg Vol (2M):
134.62K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Lantern Pharma Inc ( ) from 2020 to Jun 07 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Lantern Pharma stock (LTRN) PE ratio as of Jun 07 2024 is 0. More Details

Lantern Pharma Inc (LTRN) PE Ratio (TTM) Chart

To

Lantern Pharma Inc (LTRN) PE Ratio (TTM) Historical Data

Total 1005
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 12
Lantern Pharma PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-07 At Loss 2024-04-04 At Loss
2024-06-06 At Loss 2024-04-03 At Loss
2024-06-05 At Loss 2024-04-02 At Loss
2024-06-04 At Loss 2024-04-01 At Loss
2024-06-03 At Loss 2024-03-28 At Loss
2024-05-31 At Loss 2024-03-27 At Loss
2024-05-30 At Loss 2024-03-26 At Loss
2024-05-29 At Loss 2024-03-25 At Loss
2024-05-28 At Loss 2024-03-22 At Loss
2024-05-24 At Loss 2024-03-21 At Loss
2024-05-23 At Loss 2024-03-20 At Loss
2024-05-22 At Loss 2024-03-19 At Loss
2024-05-21 At Loss 2024-03-18 At Loss
2024-05-20 At Loss 2024-03-15 At Loss
2024-05-17 At Loss 2024-03-14 At Loss
2024-05-16 At Loss 2024-03-13 At Loss
2024-05-15 At Loss 2024-03-12 At Loss
2024-05-14 At Loss 2024-03-11 At Loss
2024-05-13 At Loss 2024-03-08 At Loss
2024-05-10 At Loss 2024-03-07 At Loss
2024-05-09 At Loss 2024-03-06 At Loss
2024-05-08 At Loss 2024-03-05 At Loss
2024-05-07 At Loss 2024-03-04 At Loss
2024-05-06 At Loss 2024-03-01 At Loss
2024-05-03 At Loss 2024-02-29 At Loss
2024-05-02 At Loss 2024-02-28 At Loss
2024-05-01 At Loss 2024-02-27 At Loss
2024-04-30 At Loss 2024-02-26 At Loss
2024-04-29 At Loss 2024-02-23 At Loss
2024-04-26 At Loss 2024-02-22 At Loss
2024-04-25 At Loss 2024-02-21 At Loss
2024-04-24 At Loss 2024-02-20 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss

Lantern Pharma Inc (LTRN) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Lantern Pharma Inc logo
Lantern Pharma Inc
NAICS : 325412 SIC : 2834
ISIN : US51654W1018

Share Class Description:

LTRN: Ordinary Shares
Description
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.